AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rosen, David B., Harrington, Kimberly H., Cordeiro, James A., Leung, Ling Y., Putta, Santosh, Lacayo, Norman, Laszlo, George S., Gudgeon, Chelsea J., Hogge, Donna E., Hawtin, Rachael E., Cesano, Alessandra, Walter, Roland B.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3539972/
https://ncbi.nlm.nih.gov/pubmed/23320091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0053518
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares